Managed Care Digest Series^® Spotlight

Screening Rates for Type 2 Diabetes Patients Continue to Recover in 2022

From 2021 to 2022, national screening rates for commercial Type 2 diabetes patients rose in four of five categories shown, following a pandemic-induced dip in screening rates in 2020.

The share of commercial Type 2 diabetes patients with select complications declined across half of the categories profiled from 2021 to 2022—CKD, DKA, and retinopathy excepted.

Click here to read the 2023 Health Care Digest ^™.

Data source: IQVIA © 2023

Key Takeaway

Despite the rising prevalence of diabetic retinopathy, screening rates among diabetes patients in the U.S. remain less than optimal. Healthy People 2030 set a goal to increase the national diabetic retinopathy screening rate to 67.7%, underscoring that social determinants of health such as insurance status, race, and income level can impact a patient's ability to receive needed screenings.³

¹ The A1c test measures the average blood glucose over the past 3 months. Figures reflect the percentage of diabetes patients who have had at least one A1c test in a given year.

² A complication is defined as a patient condition caused by diabetes. Complications of diabetes include, but are not limited to, atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), diabetic ketoacidosis (DKA), hyperglycemia, and retinopathy. ASCVD includes patients with acute coronary syndromes, myocardial infarction, stroke, and other cardiovascular diseases.

³ Lin, G., et al. (2022). Diabetic Retinopathy Screening. American Academy of Opthalmology. Retrieved from https://eyewiki.aao.org/Diabetic_Retinopathy_Screening#Screening_Rates_in_ the_United_States_and_Impact_of_Social_Determinates_of_Health. Accessed May 2023.

NOTE: Pre-2020 data are not shown.

Read More Articles >>